AMSA-LIST Archives

November 2002

AMSA-LIST@LISTS.UMN.EDU

Options: Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
From:
Reply To:
Date:
Mon, 18 Nov 2002 10:33:32 -0600
Content-Type:
text/plain
Parts/Attachments:
text/plain (61 lines)
----- Original Message -----
From: "Williams, Susan" <[log in to unmask]>
To: "AMSA International Health" <[log in to unmask]>
Sent: Monday, November 18, 2002 9:37 AM
Subject: [intlhealth] Human Trial of Global HIV Vaccine Launched


>
>
> First Human Trial of 'Global' HIV Vaccine Launched
>
> 14 November 2002
> By Alan Mozes
>
> American researchers have reached what they hope is a milestone in AIDS
> research, with the launch of the first human trial of a single AIDS
> vaccine designed to simultaneously prevent infection with the three most
> common forms of HIV.
>
> The first trial phase of the so-called "global vaccine" was launched
> yesterday [13 November] by the National Institutes of Health (NIH) in
> Bethesda, Maryland, under the supervision of the Vaccine Research Center
> (VRC).
>
> The trial vaccine incorporates modified parts of four different HIV
> genes. The genes are drawn from HIV subtype B--the most prevalent form
> of HIV in North America and Western Europe--as well as from subtypes A
> and C, which are the most common types in Africa and Asia.
>
> Copyright Reuters 2002
>
> For the Full Article, go to:
> http://reuters.com/news_article.jhtml?type=healthnews&StoryID=1742607#
>
> Vaccine Research Center
> http://www.niaid.nih.gov/vrc/
>
>
>
>
> This e-mail and any files transmitted with it may contain information that
> is PRIVILEGED, CONFIDENTIAL, and exempt from disclosure under applicable
> law.  It is intended only for the individual(s) or entity named above.  If
> you are not an intended recipient of this e-mail, you are hereby notified
> that any unauthorized use, dissemination or copying of this e-mail or the
> information contained in it or attached to it is strictly prohibited.  If
> you have received this e-mail in error, please delete it and immediately
> notify the person named above by reply e-mail.  Thank you.
>
>
>
> ---
> You are currently subscribed to intlhealth as: [log in to unmask]
> To unsubscribe send a blank email to
[log in to unmask]
>





ATOM RSS1 RSS2